C4 Therapeutics, Inc CCCC
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-02 |
| Shares Out. | 110,570,000 |
| Website | c4therapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 104 |
| Revenue | $6.2M |
| Gross Profit | $6.2M |
| Net Income | -$25.1M |
| Free Cash Flow | -$96.0M |
| Total Assets | $328.9M |
| Total Liabilities | $94.6M |
| Equity | $234.2M |
About C4 Therapeutics, Inc
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
C4 Therapeutics, Inc is a publicly traded company under the ticker symbol CCCC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)